Iovance Biotherapeutics
IOVA
257 hedge funds and large institutions have $3.88B invested in Iovance Biotherapeutics in 2020 Q2 according to their latest regulatory filings, with 74 funds opening new positions, 92 increasing their positions, 65 reducing their positions, and 34 closing their positions.
186% more call options, than puts
Call options by funds: $69.8M | Put options by funds: $24.4M
157% more capital inflows, than outflows
Capital inflows: $994M | Capital outflows: $387M
118% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 34
42% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 65
17% more funds holding
Funds holding: 219 → 257 (+38)
0.64% less ownership
Funds ownership: 96.88% → 96.25% (-0.64%)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$110M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$56.9M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$53.9M |
| 4 |
Nikko Asset Management Americas
New York
|
+$53.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$47.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$54M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$37M |
| 3 |
State Street
Boston,
Massachusetts
|
-$32.7M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$26.3M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$25.8M |
IOVA Hedge Fund Activity: Q2 2020 in Review
257 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2020, worth a combined $3.88B — up 5.7% from $3.67B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new IOVA positions and 34 closed out — a net gain of 40 holders — while 92 added to existing stakes and 65 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $110M. The largest seller was Point72 Asset Management, cutting an estimated $54M.
- 257 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2020, up from 219 in Q1 2020.
- Funds reported $3.88B of Iovance Biotherapeutics stock for Q2 2020, up 5.7% quarter-over-quarter.
- 74 funds opened new Iovance Biotherapeutics positions in Q2 2020 and 34 closed out, a net change of +40 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2020 was ARK Investment Management, an estimated $110M added.
- The largest Iovance Biotherapeutics seller in Q2 2020 was Point72 Asset Management, an estimated $54M sold.
Based on aggregated 13F filings for Q2 2020.